Plain-English translation of NCT06908993 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a targeted cancer drug called works better than standard treatment options for people with advanced lung cancer that has a specific genetic change (MET exon 14 mutation) and has gotten worse despite prior treatment. The medication is designed to target and block the MET protein, which may help slow cancer growth. Currently, this treatment is not available to patients in France, so this study aims to gather evidence that could make it accessible to patients who need it.
People in France with this specific type of lung cancer don't currently have access to newer targeted drugs like this medication, even though other countries recognize it as an important treatment option. This trial will gather evidence to help doctors and health systems decide whether this treatment should be made available and covered by insurance, while also giving patients access to a promising therapy that's shown strong results in earlier studies.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either as a daily pill or a standard treatment chosen by your doctor (such as chemotherapy, immunotherapy, or supportive care). You will have regular clinic visits for blood tests, scans, and check-ins to monitor how the cancer responds and how you're tolerating the treatment. If your cancer progresses on standard treatment, you may have the option to switch to . The study aims to follow your progress for several months to compare which treatment helps patients live longer without their cancer worsening.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.